youtube_live
Q3 2026: ieņēmumi • publicēti • Peļņa uz vienu akciju ir lielāka, nekā prognozēts +11,45% • Ieņēmumu mērķis ir pārsniegts +3,01%
Skatīt rezultātuschevron_right
AMGN34:BVMF
Amgen Inc. BDR
92,07 R$
arrow_downward
-1,82%(-1,71) 1 d.
5. nov., 16:56:00 GMT-3 · BRL
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: AMGN34…
Atvērt
94,72 R$
Augsta
94,72 R$
Zema
92,07 R$
Tirgus kapitalizācija
251,28 mljrd.
Vid. apjoms
418,00
Apjoms
160,00
Augstākā 52 ned.
94,72 R$
Zemākā 52 ned.
47,76 R$
Apgrozībā esošās akcijas
540,63 milj.
Darbinieku skaits
32 tūkst.
Atvērt
94,72 R$
Augsta
94,72 R$
Zema
92,07 R$
Tirgus kapitalizācija
251,28 mljrd.
Vid. apjoms
418,00
Apjoms
160,00
Augstākā 52 ned.
94,72 R$
Zemākā 52 ned.
47,76 R$
Apgrozībā esošās akcijas
540,63 milj.
Darbinieku skaits
32 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
The Business Journals
·
pirms 12 minūtēm
North Carolina leads U.S. in key manufacturing sector fueled by billions in investments
Yahoo Finance
·
pirms 2 stundām
What Are Amgen Investors Betting On?
The Motley Fool
·
pirms 4 stundām
Amgen vs. Pfizer: Which Healthcare Stock Is a Better Buy for 2027?
GuruFocus
·
pirms 21 stundas
Amgen Inc (AMGN) Shares Surge 3.7% -- What GF Score of 85 Tells Investors
Profils
Amgen Inc. is an American multinational biopharmaceutical company headquartered in Thousand Oaks, California. The company is ranked 18th on the list of largest biomedical companies by revenue. The name "AMGen" is a portmanteau of the company's original name, Applied Molecular Genetics.
The company's major products are Prolia and XGEVA to treat osteoporosis and bone diseases, Repatha to treat hyperlipidemia, Otezla to treat psoriasis and psoriatic arthritis, Enbrel to treat autoimmune diseases, Evenity to treat osteoporosis, Tepezza to treat Graves' ophthalmopathy, Blincyto to treat acute lymphoblastic leukemia, Nplate to regulate platelet production, Tezspire to treat asthma, Kyprolis to treat cancer, Aranesp to stimulate erythropoiesis, Krystexxa to treat gout, and Vectibix, a monoclonal antibody.
Amgen has 17 clinical programs underway in Phase III, eight in Phase II, and 19 in Phase I. Its pipeline includes MariTide, an anti-obesity medication administered once per month by injection.
The company receives approximately 80% of its revenues from sales to the three large U.S. drug wholesalers: McKesson Corporation, Cencora, and Cardinal Health. Wikipedia
Par “Amgen Inc. BDR”
ĢenerāldirektorsRobert A. Bradway
Darbinieki31,5 tūkst.
Dibināšanas datums1980
Galvenais birojsTauzandoksa, Kalifornija, Amerikas Savienotās Valstis
SektorsHealth Care
Industry-
Tīmekļa vietneamgen.com